Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign no...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Young Ju, Oh, In-Jae, Kim, Youndong, Jung, Jong Ha, Seok, Minkyoung, Lee, Woochang, Park, Cheol Kyu, Lim, Jung-Hwan, Kim, Young-Chul, Kim, Woo-Sung, Choi, Chang-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306327/
https://www.ncbi.nlm.nih.gov/pubmed/30595683
http://dx.doi.org/10.3346/jkms.2018.33.e342
Descripción
Sumario:We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ≥ 55 years of age and ≥ 30 pack-years, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. AptoDetect™-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.

Ejemplares similares